MarginsXMarginsX
Home › Markets › Health Care › ZVRA

Zevra Therapeutics Inc. (ZVRA)

ZVRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.25
+1.87% on the day
Market cap
$550.4M
Small cap
Revenue · 2025
$106.5M
+350.9% on 2024
Net income · 2025
$83.2M
78.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/0001434647-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerZVRA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001434647
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$106.5M
Net income$83.2M
Operating income-$62.9M
Net margin78.2%
Operating margin-59.1%
Revenue growth+350.9%
Cash$62.4M
Total assets$284.7M
P/E (computed)6.6×
P/S (computed)5.2×

Warning signs

Cash runway
Cash-flow positive
$122.1M cash at September 30, 2026
Share count, 1 year
+5.7%
2025-11-03 to 2026-10-30 · +64.3% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$2.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$122.1M cash; operating cash flow $9.7M a quarter.Report 2026-09-30
Shares outstanding59,504,621 (2026-10-30); 56,297,535 a year earlier; 36,218,164 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Orlando, Florida, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$37.8M$19.2M$10.0M$122.1M$0$147.8M10-Q 2026-11-03
Q2 2026
2026-06-30
$39.7M$8.8M$17.0M$145.3M$0$136.1M10-Q 2026-08-05
Q1 2026
2026-03-31
$36.2M$37.9M$6.1M$95.6M$0$122.3M10-Q 2026-05-06
Q4 2025
2025-12-31
$34.1M$12.2M$5.5M$62.4M$61.9M$106.5M10-K 2026-03-09
Q3 2025
2025-09-30
$26.1M-$544K$4.7M$54.4M$61.3M$84.4M10-Q 2026-11-03
Q2 2025
2025-06-30
$25.9M$74.7M-$3.6M$47.7M$60.7M$62.0M10-Q 2026-08-05
Q1 2025
2025-03-31
$20.4M-$3.1M-$8.2M$37.3M$60.1M$40.6M10-Q 2026-05-06
Q4 2024
2024-12-31
$12.0M-$35.7M-$16.3M$33.8M$59.5M$23.6M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52024-08-09
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEF 14A2026-04-20

Source: SEC EDGAR submissions feed, 870 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-21.7%
1 month-12.6%
3 months-18.8%
Year to date+1.3%
1 year-1.6%
From 52-week high-38.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
EVOEvotec SE$1.56-1.27%$555.0M
HELPHelus Pharma Inc.$7.67-13.53%$560.4M
WVEWave Life Sciences Inc.$2.87-8.31%$566.0M
INDPIndaptus Therapeutics Inc.$3.45+8.83%$529.9M
ACRSAclaris Therapeutics Inc.$3.60-8.04%$571.8M
CBIOCrescent Biopharma Inc.$13.50-4.59%$525.1M
CLYMClimb Bio Inc.$9.94-4.05%$583.9M
AVBPArriVent BioPharma Inc.$11.56-11.15%$597.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier